Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2021

View Archived Issues

Phase II trial evaluates CBP-201 for chronic rhinosinusitis with nasal polyps

FDA approves IND for phase I study of STP-707 in solid tumors

AstraZeneca initiates phase I/II study of AZD-0466 in advanced hematological malignancies

Novartis studies combination of VOB-560 and MIK-665 for advanced hematological malignancies

New TGF-beta inhibitor KS-356 improves experimental obesity, hepatic steatosis

Dual GIP/GLP-1 receptor agonist HISHS-2001 displays efficacy in type 2 diabetes model

Scientists describe new model of primary sclerosing cholangitis-associated cholangiocarcinoma

SciSparc to initiate phase II study of SCI-110 in patients with AD and agitation

Chinese researchers patent claudin 18.2-targeting ADCs

Roche discloses BRAF mutant inhibitors

Shaanxi Synthetic Pharmaceutical identifies new antibacterials

Chiesi Farmaceutici synthesizes new LPAR2 antagonists

Centivax patents CR-3022-derived antibodies for SARS-CoV-2

Researchers at University of Oxford initiate phase I study of HIVconsvX vaccine

To close or not to close: Astrocytes influence brain plasticity by controlling critical period

LY-3305677 is safe and shows body weight-lowering effect in FIH trial

CXD-101 demonstrates promising early clinical data in its China IND program

Atossa receives approval to open phase I/II study of AT-H201 in Australia

Dosing starts in phase I/II study of Moderna's quadrivalent seasonal flu mRNA vaccine

FDA clears IND for ASC-618 gene therapy for hemophilia A

AXA-1125 enhances insulin sensitivity in subjects with NAFLD and T2D

Ischemix awarded DoD funding to support phase I study of CMX-2043 for traumatic brain injury

Alterations in GRK5 disrupt cardiac function in murine model

Ysopia completes phase I study of Xla-1 for obesity and metabolic diseases

Batavia collaborates with RocketVax on SARS-CoV-2 vaccine candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...